Takeda Pharmaceutical (TAK): What to Watch Ahead of FY2025 Q4 Earnings
Key Takeaways
- Takeda to report FY2025 Q4 and full-year results on May 13, 2026, before U.S. market open.
- Consensus points to Q4 revenue around $7.2 billion, with full-year revenue guidance at JPY 4,530 billion ($30.2 billion).
- Company guides core revenue (Non-IFRS) for low-single-digit decline at constant exchange rates (CER), pressured by VYVANSE generics.
- Core operating profit (Non-IFRS) expected low-single-digit decline at CER, offset by cost discipline.
- Investors watching Growth & Launch Products and updates on three transformative launches.
- Q3 FY2025 saw nine-month revenue of JPY 3,411.2 billion, down 3.3% year-over-year.
Earnings Context and Why It Matters
As a longtime follower of the pharmaceutical sector, I've been keeping a close eye on Takeda Pharmaceutical (TAK), a global biopharmaceutical leader navigating a pivotal close to FY2025. The ongoing loss of exclusivity for VYVANSE since mid-2023 has weighed on sales, marking this as a transitional year. Through the first nine months, revenue fell 3.3% at actual exchange rates to JPY 3,411.2 billion, mainly due to the generics impact that's tapering but still evident. Core operating profit, however, has remained steady thanks to operational efficiencies.
For investors like us, the May 13 results will provide essential clarity on whether the company meets its full-year guidance, advances its pipeline in oncology, gastroenterology, and neuroscience, and manages the CEO transition to Julie Kim. Broader sector pressures, such as pricing challenges and favorable foreign exchange movements, make Takeda's margin sustainability and launch momentum particularly noteworthy.
Earnings Expectations
From what I see in the analyst consensus, Takeda's FY2025 Q4 (January-March 2026) revenue should come in near $7.17 billion, with some estimates reaching JPY 1.13 trillion ($7.53 billion). Full-year revenue is expected to align with the company's guidance of JPY 4,530 billion, a slight uptick from the prior forecast, driven by FX benefits and cost controls that counter the VYVANSE erosion. EPS forecasts differ somewhat, with recent Q4 estimates around $0.55 or lower, while full-year core EPS (Non-IFRS, in yen) is guided to be broadly flat.
I'll be focusing on key metrics like Growth & Launch Products revenue growth to offset the VYVANSE decline, core operating profit margin stability around 25%, and adjusted free cash flow. In Q3 FY2025, EPS of $0.48 missed the $0.55 consensus, and revenue of $7.60 billion fell short of $7.81 billion expectations, but the stock reaction was muted as attention turned to guidance upgrades. Looking ahead, FY2026 guidance—especially on launches like Qdenga—will be a highlight.
Market Reaction and Investor Sentiment
Heading into these earnings, sentiment around TAK feels cautiously optimistic. Shares are trading around $16.40, up modestly year-to-date alongside stable pharma peers. The recent Q3 miss led to limited downside, as the raised full-year outlook underscored resilience. Risks include steeper VYVANSE erosion or launch delays, while upsides could stem from cost savings or positive pipeline updates. Implied volatility points to measured expectations, with historical post-earnings moves averaging low-single digits.
Discovering Opportunities with Tickeron’s AI Screener
In my research process, I often turn to Tickeron’s AI Screener, an AI-powered tool for discovering stocks and ETFs. It lets me filter thousands of names based on technical patterns, fundamentals, trends, volatility, and AI signals—using customizable criteria like industry, market cap, indicators, price patterns, and performance metrics. This has been especially useful around earnings seasons in dynamic sectors like pharmaceuticals, helping me spot trade ideas, trending stocks, breakout candidates, and opportunities more efficiently than manual methods. It's become a go-to for data-driven decisions in my analysis.
Forward Outlook and Key Factors to Monitor
One thing that stands out is how post-earnings focus will shift to FY2026 guidance under new CEO Julie Kim, as management has emphasized this pivotal transition—balancing VYVANSE headwinds with ramping launches. I'm watching the Growth & Launch Products closely; they now represent nearly half of revenue and could accelerate in areas like ENTIVIO in gastroenterology and oncology assets.
Three transformative launches—potentially including the Qdenga dengue vaccine scaling to 100 million doses by 2030—hold potential to drive a rebound. Cost trends are critical too: The multi-year efficiency program aims to recover core operating profit margins to the low-to-mid 30s, offsetting R&D and launch investments. Keep an eye on FX assumptions, which have provided tailwinds lately, and pricing pressures in key markets.
Demand in neuroscience and rare diseases, along with pipeline milestones like ADAMTS13 for thrombotic thrombocytopenic purpura (TTP), will influence long-term growth. Free cash flow continues to support dividends and buybacks, with Q3 adjusted FCF up 10% year-to-date.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
TAK sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for TAK moved above the 200-day moving average on August 10, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 13, 2026. You may want to consider a long position or call options on TAK as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for TAK just turned positive on August 11, 2026. Looking at past instances where TAK's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TAK advanced for three days, in of 312 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 254 cases where TAK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for TAK moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TAK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
TAK broke above its upper Bollinger Band on August 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.213) is normal, around the industry mean (47.174). P/E Ratio (41.878) is within average values for comparable stocks, (94.151). Projected Growth (PEG Ratio) (0.410) is also within normal values, averaging (2.206). Dividend Yield (0.035) settles around the average of (0.029) among similar stocks. P/S Ratio (1.963) is also within normal values, averaging (177.105).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TAK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a pharmaceutical products manufacturer
Industry PharmaceuticalsGeneric
Advertisement